S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
Log in
NASDAQ:ZLAB

Zai Lab Stock Forecast, Price & News

$170.90
+6.97 (+4.25 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$164.77
Now: $170.90
$171.79
50-Day Range
$106.15
MA: $125.35
$163.93
52-Week Range
$43.06
Now: $170.90
$171.79
Volume664,533 shs
Average Volume367,420 shs
Market Capitalization$9.93 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.95
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, autoimmune, and infectious diseases in China. The company offers Niraparib, an oral small molecule poly ADP ribose polymerase 1/2 inhibitor for the treatment of multiple solid tumors, including ovarian and other types of lung cancer; and Optune, a cancer therapy for the treatment of glioblastoma multiforme. It also develops Ripretinib, a switch control inhibitor for the treatment of KIT and/or PDGFRa-driven cancers, including gastrointestinal stromal tumors, systemic mastocytosis, and other cancers; REGN1979 for the treatment of diffuse large B-cell lymphoma and follicular lymphoma; Margetuximab an immune-optimized anti-HER2 monoclonal antibody for the treatment of breast and gastric cancers; and INCMGA0012, an investigational monoclonal antibody for the treatment of MSI-high endometrial cancer. In addition, the company develops Bemarituzumab, a humanized monoclonal antibody for the treatment of gastric and gastroesophageal cancers; Omadacycline, an antibiotic to treat acute bacterial skin and skin structure, and community-acquired bacterial pneumonia infections; and Durlobactam for the treatment of acinetobacter baumannii bacterial infections. Zai Lab Limited has license and collaboration agreements with the TESARO Inc.; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; and Incyte Corporation. The company was founded in 2013 and is headquartered in Shanghai, China.
Zai Lab logo

MarketRank

Overall MarketRank

1.22 out of 5 stars

Medical Sector

667th out of 1,480 stocks

Pharmaceutical Preparations Industry

339th out of 612 stocks

Analyst Opinion: 1.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZLAB
CUSIPN/A
Phone86-21-6163-2588
Employees859

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.98 million
Book Value$5.07 per share

Profitability

Miscellaneous

Market Cap$9.93 billion
Next Earnings Date3/18/2021 (Estimated)
OptionableOptionable
$170.90
+6.97 (+4.25 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZLAB News and Ratings via Email

Sign-up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions

How has Zai Lab's stock been impacted by Coronavirus?

Zai Lab's stock was trading at $50.13 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ZLAB stock has increased by 240.9% and is now trading at $170.90.
View which stocks have been most impacted by COVID-19
.

Is Zai Lab a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zai Lab stock.
View analyst ratings for Zai Lab
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Zai Lab?

Wall Street analysts have given Zai Lab a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zai Lab wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Zai Lab's next earnings date?

Zai Lab is scheduled to release its next quarterly earnings announcement on Thursday, March 18th 2021.
View our earnings forecast for Zai Lab
.

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) posted its quarterly earnings data on Thursday, March, 19th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by $0.05. The business earned $4.65 million during the quarter.
View Zai Lab's earnings history
.

What price target have analysts set for ZLAB?

4 analysts have issued twelve-month target prices for Zai Lab's stock. Their forecasts range from $95.00 to $111.00. On average, they anticipate Zai Lab's share price to reach $105.67 in the next year. This suggests that the stock has a possible downside of 38.2%.
View analysts' price targets for Zai Lab
or view Wall Street analyst' top-rated stocks.

Who are some of Zai Lab's key competitors?

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology Group (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

Who are Zai Lab's key executives?

Zai Lab's management team includes the following people:
  • Dr. Ying Du, Founder, Chairwoman & CEO (Age 54)
  • Mr. Tao Fu, Pres, COO & Director (Age 48)
  • Mr. Ki Chul Cho, Chief Financial Officer (Age 42)
  • Dr. Harald Reinhart M.D., Chief Medical Officer of Autoimmune & Infectious Diseases (Age 68)
  • Mr. Yi Liang M.B.A., M.D., Chief Commercial Officer & Pres of Greater China (Age 49)
  • Mr. F. Ty Edmondson, Chief Legal Officer
  • Dr. Ning Xu M.D., Exec. VP & Head of Clinical Operations (Age 55)
  • Dr. Jonathan J. Wang, Sr. VP & Head of Bus. Devel. (Age 38)
  • Dr. James Yan DABT, M.D., Ph.D., Chief Operating Officer of R&D (Age 56)
  • Dr. Yunpeng Su M.D., VP & Head of Biologics Discovery - China (Age 45)

When did Zai Lab IPO?

(ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by a variety of institutional and retail investors. Top institutional investors include E Fund Management Hong Kong Co. Ltd. (0.03%).

Which institutional investors are buying Zai Lab stock?

ZLAB stock was purchased by a variety of institutional investors in the last quarter, including E Fund Management Hong Kong Co. Ltd..

How do I buy shares of Zai Lab?

Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $170.90.

How big of a company is Zai Lab?

Zai Lab has a market capitalization of $9.93 billion and generates $12.98 million in revenue each year. The company earns $-195,070,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis. Zai Lab employs 859 workers across the globe.

What is Zai Lab's official website?

The official website for Zai Lab is www.zailaboratory.com.

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.